Since the publication of the “European Guideline for the investigation and initial therapy of HUS” significant progress has been made in the therapy of HUS with the clinical verification of the efficacy of eculizumab [8], an anti-C5 monoclonal antibody based inhibitor of the complement terminal pathway. The gene discussed is C5; the disease is hemolytic-uremic syndrome.